<?xml version="1.0" encoding="UTF-8"?>
<p>Major limitation of all reported case series is the absence of matched control subjects who were not on convalescent plasma therapy. Although empirical experience with plasma therapies during previous coronavirus epidemics alerted physicians of the risk of anaphylactic reactions, transfusion-related acute lung injury, and hemolysis,
 <xref rid="B43" ref-type="bibr">43</xref> no serious adverse effects have been reported during the current pandemic.
</p>
